Cannabinoids exert antiproliferative effects in a wide range of tumoral cells, including hepatocellular carcinoma (HCC) cells. In this study, we examined whether the PPARc-activated pathway contributed to the antitumor effect of two cannabinoids, D9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells. Both cannabinoids increased the activity and intracellular level of PPARc mRNA and protein, which was abolished by the PPARc inhibitor GW9662. Moreover, genetic ablation with small interfering RNA (siRNA), as well as pharmacological inhibition of PPARc decreased the cannabinoid-induced cell death and apoptosis. Likewise, GW9662 totally blocked the antitumoral action of cannabinoids in xenograft-induced HCC tumors in mice. In addition, PPARc knockdown with siRNA caused accumulation of the autophagy markers LC3-II and p62, suggesting that PPARc is necessary for the autophagy flux promoted by cannabinoids. Interestingly, downregulation of the endoplasmic reticulum stress-related protein tribbles homolog 3 (TRIB3) markedly reduced PPARc expression and induced p62 accumulation, which was counteracted by overexpression of PPARc in TRIB3-knocked down cells. Taken together, we demonstrate for the first time that the antiproliferative action of the cannabinoids THC and JWH-015 on HCC, in vitro and in vivo, are modulated by upregulation of PPARc-dependent pathways.
Hepatocellular carcinoma (HCC) is the most frequent primary solid tumor of the liver, and it is estimated to account for 5% of all malignant neoplasias. 1, 2 Its aggressiveness and extensive dissemination lead to poor patient prognosis. Although there has been a great research effort made in order to come up with efficient therapeutic strategies, the incidence and mortality of HCC have increased in the United States and Europe in the past decade and therefore innovative research findings are necessary to understand the etiology of cancer and to improve the treatment and survival of patients.
Cannabinoids are bioactive lipids that have been shown to modulate many physiological and pathological conditions. In particular, it has been previously described that cannabinoids arrest cell proliferation, reduce cell migration and inhibit angiogenesis, and therefore, cannabinoid-like compounds offer a therapeutic potential for the treatment of many types of cancer. [3] [4] [5] Although the well-defined cannabinoid receptors are the GPCR receptor types CB 1 and CB 2 , cannabinoids may impact other putative targets such as nuclear receptors PPARs. 6, 7 PPARs are ligand-activated transcription factors, which belong to the nuclear receptor superfamily and mediate several physiological functions, among which the best characterized are lipid metabolism, energy balance and antiinflammation. 8 There are three PPAR subtypes: alpha, delta (also known as beta) and gamma, all of which have long been known to be expressed in the liver, although at different levels. 9 PPARg exists in two major isoforms (g 1 and g 2 ) that
arise by differential transcription start sites and alternative splicing, 10 albeit PPARg 1 expression is very low in most tissues including the liver. PPARg is involved in liver lipid synthesis and storage, and despite its relatively low levels in healthy liver it has a relevant role in several liver pathologies such as liver steatosis, fibrosis and HCC. Although the role of PPARg in the development of liver diseases with different aetiologies has led to controversial results, there is a general consensus about the fact that increased PPARg activity can counteract the occurrence and progression of cancer in the liver. Several PPARg ligands have been shown to reduce HCC cell proliferation and migration through PPARg activation. [11] [12] [13] [14] [15] Moreover, recent findings using PPARg knockout mice suggest that PPARg reduces HCC carcinogenesis and acts as a tumor-suppressor gene in the liver. 16 Many current lines of evidence indicate that there is a cross talk between death signalling pathways and PPARg activity in several cancer cell types. 17 It has been demonstrated that the synthetic cannabinoid WIN 55,212-2 (WIN) induces apoptosis in the HCC HepG2 cell line, which is associated with an increase in PPARg expression. 18 We have previously described that the cannabinoids D 9 -tetrahydrocannabinol (THC), the main psychoactive component of the Cannabis sativa plant, and JWH-015, a synthetic selective ligand of CB 2 , exert antiproliferative effects and induce autophagy on the HCC cell lines HepG2 and HuH-7. 19 As cannabinoids have well-known palliative effects on some cancer-associated and chemotherapy-related symptoms, and they are being therapeutically used for this purpose, it is necessary to further study the antitumoral properties of cannabinoids for a better management of those compounds. In this study, we investigated whether PPARg is involved in the antiproliferative effect of cannabinoids on HCC cells and its relationship with the previously identified signalling pathways.
Results
The cannabinoids THC and JWH-015 activate PPARc in HCC cells. To investigate the role of PPARg in the mechanism of action of cannabinoids on HCC cells, we treated HepG2 cells with the cannabinoids THC and JWH-015, after which PPARg expression was examined using RT-PCR and western blot. As shown in Figure 1a , there was a peak of PPARg mRNA at 1-h treatment with both cannabinoids and a further decline at 24 h. Likewise, PPARg protein expression increased until 3 h and then decreased at 8 h (Figure 1b) . As a further proof of PPARg induction, we measured the PPARg target CD36 to confirm PPARg activation. As shown in Figure 1c , THC and JWH-015 produced an increase in CD36 mRNA levels with a peak at 6 h of treatment. Lipid accumulation in liver cells is considered an indicator of PPARg activation. Therefore, we measured neutral lipid content in HepG2 and HUH-7 cells by Oil Red O staining. Neutral lipid accumulated in both HepG2 and HUH-7 cells after THC and JWH-015 treatment. The increase in Oil Red O staining was prevented by pretreatment with the PPARg antagonist GW9662, confirming the involvement of PPARg in neutral lipid accumulation and PPARg activation after cannabinoids treatment (Figure 2a ). Confocal microscopy of HepG2 cells treated with THC and JWH-015 also showed a neutral lipid accumulation within the cell (Figure 2c) . Therefore, these data demonstrated that cannabinoids treatment activates PPARg in HCC cells.
The activation of PPARg by cannabinoids may be performed by direct binding to the receptor or by intracellular signalling cascades that may lead indirectly to PPARg activation. The mechanism of action of THC on PPARg has been extensively studied by O'Sullivan and Kendall, 20 but it is unknown if JWH-015 can activate PPARg directly. To investigate whether JWH-015 joined PPARg, we performed a binding assay using HeLa cells with a reporter luciferase gene. However, JWH-015-induced PPARg activation was not due to an agonist activity of the compound, as JWH-015 was not able to bind to the ligand-binding domain of PPARg in the in vitro assay (Figure 2c ), suggesting that PPARg activation AMPK and PPARc are two independent pathways activated by cannabinoids. We have previously shown that THC and JWH-015 stimulate autophagy on HCC cells through two different pathways: (i) activation of adenosine monophosphate-activated kinase (AMPK) via CaMKKb, and (ii) ER stress with upregulation of tribbles homolog 3 (TRIB3) and subsequent inhibition of the serine-threonine kinase Akt/ mammalian target of rapamycin C (Akt/mTORC1) axis. 19 Furthermore, AMPK has been shown to participate in modulating the activity of PPARg, 21 thus providing a possible mechanism for cross talk between the signaling pathways activated by cannabinoids. PPARg phosphorylation by AMPK represses both the ligand-dependent and independent transactivating function of the receptor. Therefore, we examined whether the activities of these molecules by cannabinoids were coordinately regulated. To investigate the relationship between these two pathways, we knocked down AMPK and measured PPARg levels after cell treatment with THC and JWH-015. Both cannabinoids, THC and JWH-015, were able to increase PPARg levels even when AMPK was absent (Figure 3a) . These findings indicate that AMPK is not necessary for PPARg induction by cannabinoids. Moreover, PPARg is not necessary for AMPK activation by cannabinoids, as downregulation of PPARg did not reverse the increase in AMPK phosphorylation produced by THC or JWH-015 (Figure 3b ). Therefore, these data suggest that AMPK and PPARg are two independent pathways activated by cannabinoids in HCC.
The TRIB3 protein regulates PPARc expression in HCC cells. To investigate whether PPARg induction was associated with the second mechanism by which cannabinoid induced cell death (ER stress/Akt/mTORC1 axis), we analysed this pathway in cells in which PPARg was genetically blocked. However, PPARg knockdown did not modify the inhibition of the Akt pathway and S6 phosphorylation or the increase in eIF2a phosphorylation, which we had previously reported to be modified after cannabinoids treatment (Figure 3b ).
The intracellular adaptor TRIB3, a human homolog of Drosophila tribbles, has been found to interact with a variety of signalling molecules to regulate diverse cellular functions including cell proliferation, migration and morphogenesis by participating in protein complex assembly. In the liver, it functions as a negative regulator of the serine-threonine kinase Akt. We have previously shown that TRIB3 links cannabinoid-induced ceramide production and endoplasmic reticulum stress with Akt inhibition and autophagy in HCC cells. 19 Recent research has shown that in 3T3-L1 adipocytes TRIB3 interacts with PPARg to modulate its transcriptional activity. 22 To investigate the role of TRIB3 in the action mechanism of cannabinoids, HCC cells were transfected with selective TRIB3 siRNA, treated with THC or JWH-015, and examined for PPARg protein and mRNA expression. As shown in Figure 3c , when TRIB3 was knocked down, levels of PPARg were virtually undetectable, both in control cells and in cannabinoid-treated cells, being even more effective than PPARg silencing. This means that TRIB3 is necessary for PPARg expression and suggests a new PPARg regulatory pathway to be explored in further research.
PPARc contributes to cannabinoid-induced autophagy.
Owing to recent data about the involvement of PPARg in autophagy 23, 24 and as this process is necessary for the antitumoral action of cannabinoid, 19, 25 we wondered whether PPARg receptor might also have a role in the autophagy induced by cannabinoids on HCC cells. To investigate this effect, we analyzed LC3-II levels, a hallmark of autophagy, in cannabinoid-treated cells. As shown in Figure 4 , THC and JWH-015 induced an increase in LC3II, as was expected, measured by western blot (a) or confocal microscopy (b). Surprisingly, knocking down of PPARg increased LC3II even in the control cells. Likewise, cells treated with cannabinoids showed higher LC3II levels when PPARg was knocked down than when cells were transfected with the control siRNA. To investigate whether this increase was caused by an augmented activation of autophagy, levels of the signal adaptor protein p62, an autophagosome cargo that is the cell, because they are acidic organelles filled with hydrolases. Among the lysosomal hydrolases, proteases, especially cathepsins, have a major role. Similar to other proteases, the cathepsins are synthesized as inactive proenzymes and are activated by proteolytic removal of the N-terminal propeptide. As shown in Figure 4a , THC and JWH-015 increased the levels of cathepsines D and L (both inactive and active forms). However, PPARg knockdown did not modify these increases, suggesting that PPARg does not regulate cathepsin L or D in this model. Cysteine cathepsins are optimally active in a slightly acidic pH, and are mostly unstable at neutral pH. When cathepsins are outside the lysosomes or if there is no acidic pH within the lysosome, they can be relatively rapidly inactivated and proenzymes accumulate. 28 As SiControl and SiPPARg-untreated or cannabinoid-treated cells had a right cleavage of these proteases and the same level of the lysosomal marker LAMP-2, we can conclude that lysosomes work correctly, suggesting that the reason for autophagosome accumulation is not lysosome failure. This is in concordance with the observation that PPARg silencing causes an accumulation of LC3 even in control cells (Figures 4a and b) . Therefore, we can conclude that in HCC cells cannabinoids induce autophagy through PPARg activation (summarized in Figure 4d ). PPARc participates in the antiproliferative effect evoked by cannabinoids. It has been recently described that the cannabinoid WIN induces apoptosis through PPARg in HepG2 cells. 18 Moreover, in previous studies, we demonstrated that cannabinoids induce apoptosis and autophagy in HCC cells and in xenograft tumor models. To investigate the role of PPARg in the anti-proliferative response exerted by THC or JWH-015, HCC cells were incubated with increasing doses of both cannabinoids for 48 h in the presence of the PPARg-selective antagonist GW9669 and cell viability was measured by MTT. Pharmacological inhibition of PPARg caused a shift of the dose-response curve to the right, thus increasing the IC50 dose in HepG2 and in HUH-7 cells (Figure 5a ). Moreover, when HepG2 cells or HuH-7 cells were transfected with PPARg siRNA, the inhibitory effect of cannabinoids on cell viability was reduced ( Figure 5b ). As PPARg agonists have been evaluated as potential antitumoral agents, we decided to test the possible synergic effect between cannabinoids and the PPARg agonist Troglitazone (TRO) in combinatorial treatment. In agreement with the results obtained by other groups, 16 ,29-33 we observed that TRO treatment produced a dose-dependent reduction in cell viability that reached a value of 50% when 40 mM concentrations were used (Figure 5c ). We therefore selected submaximal doses of Troglitazone (20 mM), THC (2 mM) and JWH-015 (2 mM) to evaluate whether the combined administration of PPAR ligands and cannabinoids enhanced their ability to reduce cell viability. In line with this possibility, combined treatment with low doses of TRO and THC or JWH-015 reduced the viability of HepG2 cells (Figure 5d ).
To further investigate the role of PPARg in cannabinoidinduced cell death, we measured the number of apoptotic Anexin-V and IP-stained cells by cytometry. Both THC and JWH-015 increased the number of apoptotic cells, which was reduced by pharmacological inhibition of PPARg with GW9669 ( Figure 6 ). According to this, GW9669 also reduced the cleavage of procaspase 3 induced by cannabinoids (data not shown). These observations support the fact that PPARg participates in cell death induced by cannabinoids.
PPARc is involved in the in vivo antitumor properties of cannabinoids. As a further proof for the involvement of PPARg in the antitumoral action of cannabinoids, we generated tumor xenografts by subcutaneous inoculation of HepG2 cells in nude mice. Mice were treated peritumorally with THC or JWH-015 alone or in combination with the PPARg inhibitor GW9662, and tumor size was daily monitored. As shown in Figure 7 , THC and JWH-015 significantly reduced the tumor growth rate. However, when tumors were treated with the cannabinoids in the presence of the PPARg antagonist, the tumor growth was similar to those of the controls. Furthermore, we analyzed PPARg mRNA expression of HepG2-and HuH-7-derived tumors, and we found that cannabinoid treatment increased PPARg mRNA levels in both cases (Figure 7b ). Thereby, in vivo antitumor effect of cannabinoids in HCC cells depends on PPARg activation.
Discussion
The prevalence and severity of HCC is increasing worldwide and prognosis of HCC patients is still unsatisfactory owing to the high rate of recurrence and metastasis. Therefore, the improvement of therapeutic strategies for HCC patients is critical for the management of HCC. The active ingredients of Cannabis sativa plant, as well as their synthetic analogues, emerge nowadays as new anticancer drugs as they exert antitumor properties in a wide range of tumor cell types including HCC cells. During the past few years, much effort has been taken to understand the molecular mechanisms involved in the antitumoral action of cannabinoids. We have recently published that THC and JWH-015 induce autophagy in HCC cells by activating the AMPK pathway. 19 In this study, we report the involvement of PPARg activation in the anticancer effect of cannabinoids. We show that both THC and JWH-015 increase mRNA and protein levels of PPARg in a time-dependent fashion and induce PPAR activation in vitro. The activation of PPARg is not produced by direct binding of cannabinoids to PPARg. It has been shown that PPARg may be phosphorylated by different kinases including AMPK, which can modulate PPARg activity. 21 As we had previously observed that cannabinoids induce AMPK activation in HCC cells, we wonder whether AMPK was responsible for cannabinoid-induced PPARg activation. However, genetic downregulation of AMPK did not have any effect on PPARg induction exerted by cannabinoids. Moreover, genetic inhibition of PPARg did not have any effect on AMPK phosphorylation or Akt/mTOR/S6 axis activation in cannabinoid-treated cancer cells, suggesting that PPARg did not have a role in those pathways. Therefore, although modulation of both AMPK and PPARg signalling might be responsible for the antiproliferative effect of cannabinoids, a cross talk between them was not found in our study (summarized in Figure 4d ). Our results are in contrast with recent research showing that activation of AMPK inhibits transcriptional activity of PPARg in HepG2 cells. 34 However, in this study, the effects of AMPK did not appear to be mediated through effects on PPARg binding to DNA and were independent of the kinase activity. 34 The role of PPARg in cannabinoid-induced cell death was primarily concluded from the pharmacological blockage of cell death by compound GW9662, a PPARg selective antagonist, and further confirmed by knockdown of PPARg expression. In line with this, previous data have evidenced a PPARgdependent process in WIN-induced HepG2 cell death. 18 However, in vivo involvement of PPARg in the cannabinoids' antitumoral action has not been demonstrated before. We show here that pharmacological inhibition of PPARg in vivo blocks the antitumoral effect of cannabinoids in HCC xenografts.
The antitumor activity of cannabinoids against HCC cells has been related to the ability of these drugs to induce apoptosis and autophagy. Our results show that when PPARg is inhibited with GW9662 or genetically knocked down, cannabinoids fail to induce apoptosis. To note, when PPARg expression is silenced, there is an increase of LC3-II and p62, not only in the cannabinoid-treated cells but even in the control cells. This suggests that when PPARg is absent, autophagy is blocked after autophagosome formation and therefore LC3II increases and p62 accumulates in the autophagosome because it cannot be further degraded (Figure 4d) . Our studies about lysosomal functionality suggest that this organelle operates appropriately, because procathepsins are cleaved and lysosomes are not accumulated. Studies performed by Jiang et al. 24 in PPARg-deficient mice showed accumulated autophagic vacuoles and upregulated autophagic marker LC3 protein expression. This is in agreement with our observations, which provide a mechanistic link between a PPARg receptor and autophagy-essential proteins in mammalian hepatocellular cells. These results are in line with a recent study showing a specific induction of autophagy by PPARg activation in breast cancer cells. 23 It has been previously described that cannabinoids cause endoplasmic reticulum stress and increase of the pseudokinase protein TRIB3, which links ER stress to autophagy in cannabinoids' antitumoral action. 25, 35, 36 Our results show that when TRIB3 is genetically inhibited, it dramatically decreases the expression of both PPARg mRNA and protein. Recent studies performed by Takahashi et al. 22 demonstrated that TRIB3 downregulates PPARg transcriptional activities by protein-protein interaction in 3T3-L1 adipocytes. Moreover, it has previously been shown that ceramide induces HepG2 cell apoptosis through PPARg activation. 37 Our data show that cannabinoid treatment increases phosphorylated-eIF2a, an ER stress marker, and that the ER stress-related pseudokinase TRIB3 is necessary for cannabinoid-induced cell death and PPARg activation. We have also observed that cannabinoids induce ceramide accumulation in HepG2 cells (data not shown), which could link cannabinoid-induced ER stress with inhibition of cell proliferation via PPARg activation. Here, we provide the first evidence that TRIB3 has a crucial role in regulating cannnabinoid-induced PPARg overexpression. Western blot. After different treatments according to the experiments, cells were lysed in ice-cold lysis buffer (50 mM Tris pH 7.4, 0.8 M NaCl, 5 mM MgCl 2 , 0.1% Triton X-100, 1 mM PMSF, 10 mg/ml soybean trypsin inhibitor, 1 mg/ml aprotinin and 5 mg/ml leupeptin), and cleared by microcentrifugation. Equivalent protein amounts of each sample were separated on SDS-PAGE gels and blotted to PVDF transfer membrane. After blocking with 5% skim-dried milk, immunoblot analysis was performed followed by enhanced chemoluminescence detection as previously described.
38
DNA-binding ELISA for activated PPARc transcription factor. Cells were treated with cannabinoids as explained in the figure legends, and scraped on washing buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl 2 , 10 mM, KCl, 1 mM DTT, 0.5 mM PMSF, 5 mM NaF, 2 mg/ml leupeptin, 10 mg/ml aprotinin), and then lysed in washing buffer þ 0.5% NP-40 for 30 min at 4 1C. Then, the nuclear extract was obtained by centrifugation at 15 000 Â g for 30 min at 4 1C. To determine whether the treatment activated PPARg, 10 mg nuclear extract was incubated in a 96-well plate to which oligonucleotide containing the peroxisome proliferator response element had been immobilized (Active Motif, Rixensart, Belgium). PPARs contained in nuclear extracts bind specifically to this oligonucleotide and are detected through use of an antibody directed against PPARg. Addition of a secondary antibody conjugated to horseradish peroxidase provides a sensitive colorimetric readout that is quantified by spectrophotometry. Unspecific binding is monitored by competition with an oligonucleotide containing the consensus PPARg response element sequence, according to the manufacturer's protocol. Confocal microscopy. After 48 h in culture, the cells were fixed in 4% paraformaldehyde in phosphate-buffered saline and incubated. Immunolabelling of neutral lipid with Lipidtox (Invitrogen) was performed by incubation at room temperature for 1 h. Imaging was with a Leica TCS SP5 laser-scanning confocal microscope with LAS-AF imaging software, using a Â 63 oil objective.
Cell viability assay. Cells in logarithmic phase were cultured at a density of 5000 cells/cm 2 in a 12-well plate. After treatments, as explained in the figure legends, cell viability was assayed by MTT as previously described, 19, 39 to evaluate the effects of cannabinoids on cell growth. siRNA tranfections. Cells were then transfected in 1 ml OPTIMEN containing 4 mg lipofectamine 2000 (Invitrogen), with 100 nM PPARg, AMPK or TRIB3 specific siRNA duplexes (PPARg: 5 0 -CCAAGUUUGAGUUUGCUGUdTdT-3 0 and 5 0 -ACAGCAAACUCAAACUU GGdTdT-3 0 ; AMPK: 5 0 -CCCAUAUUAUUUGCGUGUAdTdT-3 0 and 5 0 -UACACGCCAAAUAAUAUGGGdTdT-3 0 ; TRIB3: 5 0 -GUGC-GAAGCCGCCAC CGUAdTdT-3 0 and 5 0 -UACGGUGGCGGCUUCGCACdTdT-3 0 ) (Sigma) or control scrambled RNA for 12 h according to the manufacturer's protocols (Invitrogen). At 24 h after transfection, the medium was removed and replaced for DMEM containing 10% fetal bovine serum. At dedicated time points after transfection, cells were used for MTT cell viability assays or western blot.
PPAR gamma expression vector and transient transfections.
The PPARg expression vector pCMX-mPPARg was generously provided by Dr. Mercedes Ricote (CNIC, Madrid, Spain). HepG2 cells were transiently transfected using 4 ml Lipofectamine LTX & Plus Reagent (Invitrogen) with 3 mg of the expression vector in 0.2-ml OPTIMEN, according to the manufacturer's protocols (Invitrogen). At 48 h after transfection, the experiments were performed with the different treatments.
Animal study. Forty-eight (48) male athymic nude (nu/nu) mice aged 5 weeks were purchased from Harlan Iberica Laboratory (Barcelona, Spain) and housed under specific pathogen-free conditions in a 12-h light-dark cycle at 21-23 1C and 40-60% humidity. All animal studies were conducted in accordance with the Spanish institutional regulation for the housing, care and use of experimental animals with the approval of the Institutional Animal Care and Use Committee of Alcala University and met the European Community directives regulating animal research. Recommendations made by the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) have been kept carefully.
After 1 week adaptation period, mice were injected subcutaneously in the right flank with 10 Â 10 6 HepG2 cells in 0.1 ml of phosphate-buffered saline þ 0.5% BSA to induce HCC tumors. Two weeks after transplantation, tumors had grown to an average volume of 150 mm 3 . Then, the mice were equally divided into six groups (n ¼ 8) and daily treated with vehicle, 15 mg/kg THC or 1.5 mg/kg JWH-015 in the presence or absence of 1 mg/kg GW9662 for 15 days. After treatment, tumors were dissected and weighed.
Statistical analysis. Data are presented as the mean ± S.E. of the number of experiments indicated. Significance of differences between groups was tested by paired Student's t-test using the SPSS statistical software (Chicago, IL, USA). Differences between groups were considered significant when Po0.05.
Conclusions
We here illustrate that the cannabinoids THC and JWH-015 exert antitumor effect against the human HCC cell lines HepG2 and HUH-7 in vitro and in vivo through PPARg. The activation of PPARg by cannabinoids is independent of the signaling cascades previously described. However, it links endoplasmic reticulum stress with autophagy. TRIB3 is necessary for PPARg expression in HCC cells, which collaborates in the autophagy flux.
